Isaac Blech
CIK 905536 · last filed 2019-05-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MDGN.WS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
321 COLUMBUS AVENUE
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CONTRAFECT Corp (CFRX) Delisted | Director | 20 | $0.05 | $1 | $19.8K | 4 | 2019-05-29 |
| XFOR | Director | — | $3.28 | — | $0 | 2 | 2019-04-02 |
| PDSB | Director | 10,000 | $1.09 | $10.9K | $0 | 2 | 2019-03-18 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Director | — | $2.93 | — | $0 | 1 | 2019-01-02 |
| Avalo Therapeutics, Inc. (CERCW) Delisted | Director | — | — | — | $0 | 8 | 2018-10-01 |
| EDGE | Director | — | $52.10 | — | $0 | 4 | 2018-08-15 |
| Avalo Therapeutics, Inc. (CERCZ) Delisted | Director | — | — | — | $0 | 2 | 2017-04-04 |
| InspireMD, Inc. (NSPR.WS) Delisted | Director | — | $0.05 | — | $0 | 1 | 2016-12-15 |
| Avalo Therapeutics, Inc. (CERC.Z) Delisted | Director | — | — | — | $0 | 3 | 2016-10-03 |
| NSPR | Director | — | $0.45 | — | $0 | 2 | 2016-07-06 |
| CONTRAFECT Corp (CFRX.W) Delisted | Director | — | — | — | $0 | 1 | 2016-05-11 |
| Aevi Genomic Medicine, LLC (MDGN) Delisted | Director | — | — | — | $0 | 1 | 2016-04-19 |
| Avalo Therapeutics, Inc. (CERC.U) Delisted | Director | 588,904 | — | — | $0 | 2 | 2015-11-12 |
| Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Director | 1,896,828 | — | — | -$944.5K | 8 | 2015-09-23 |
| CONTRAFECT Corp (CFRX.Z) Delisted | Director | — | — | — | $0 | 2 | 2015-05-06 |
Recent Filings · Page 5 of 8
79 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-11-17 | — | Mixed | — | $0 | |
| 2015-11-12 | Avalo Therapeutics, Inc. (CERC.U) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-10-20 | Avalo Therapeutics, Inc. (CERC.U) Delisted | Conv (C) | +187,982 | $0 | EDGAR |
| 2015-09-23 | Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Mixed | +135,532 | $7 | EDGAR |
| 2015-09-21 | — | Mixed | — | $0 | |
| 2015-09-21 | — | Grant (A) | — | $0 | |
| 2015-08-14 | — | Mixed | — | $0 | |
| 2015-05-06 | CONTRAFECT Corp (CFRX.Z) Delisted | — | — | $0 | EDGAR |
| 2015-02-20 | Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-02-10 | CONTRAFECT Corp (CFRX.Z) Delisted | — | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.